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Purpose: The purpose of this study was to compare and quantify the expression of C-reactive protein (CRP), matrix metallo-
proteinase (MMP)-14, and tissue inhibitor of metalloproteinases (TIMP)-2 in gingival tissues of patients with chronic periodon-
titis accompanied with inflammatory reaction related to alveolar bone resorption with or without type 2 diabetes mellitus (DM). 
Methods: Twelve patients with type 2 DM and chronic periodontitis (group 3), twelve patients with chronic periodontitis (group 
2), and twelve healthy individuals (group 1) were included in the study. Gingival tissue biopsies were collected from each pa-
tient and from healthy individuals at the time of periodontal surgery (including surgical crown lengthening) or tooth extrac-
tion. The concentrations of cytokines were determined by a western blot analysis.
Results: The expression levels of CRP and MMP-14 increased in group 2 and 3, and they were highest in group 3. The expres-
sions of TIMP-2 also increased in group 2 and 3. 
Conclusions: This study demonstrated that the expression levels of CRP, MMP-14, and TIMP-2 might be inflammatory mark-
ers in periodontal inflamed tissue. It can be assumed that CRP, MMP-14, and TIMP-2 may be partly involved in the progres-
sion of periodontal inflammation associated to type 2 DM.
Keywords:  Chronic periodontitis, Type 2 diabetes mellitus, C-reactive protein, Matrix metalloproteinase 14, Tissue inhibitor of 
metalloproteinase-2.
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INTRODUCTION
Diabetes mellitus (DM) is the most common metabolic dis-
ease worldwide. More than 90% of DM patients have type 2 
diabetes [1]. DM is the leading cause of blindness [2], renal 
failure, and lower limb amputations. DM is a major risk fac-
tor for cardiovascular disease, stroke, neuropathy, and peri-
odontitis [1,3]. 
Chronic periodontitis is the most common type of periodon-
tal disease, and results from extension of the inflammatory 
process initiated by bacteria in the gingiva to the supporting 
periodontal tissues. A reciprocal relationship exists between 
DM and periodontal disease [4]. Periodontal infections, like 
other infections, have a significant impact on diabetic con-
trol.
Conversely, DM is a significant risk factor for the develop-
ment of periodontal disease and aggravates the severity of 
periodontal infections [5]. The comorbidity of these two in-
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flammatory diseases suggests that there are common ele-
ments of pathogenesis related to the risks for both conditions.
In patients with periodontal disease, chronic low-level sys-
temic exposure to periodontal microorganisms may occur, 
leading to significant changes in the plasma levels of cyto-
kines and hormones. Due to the dynamic nature of the in-
flamed periodontium, the tissue may serve as an endocrine-
like source of inflammatory mediators. Among the inflam-
matory biomarkers examined, C-reactive protein (CRP), and 
Interleukin (IL)-6 appear to be involved, according to plausi-
ble biological mechanisms through which they function, ex-
amined in studies of the links between periodontal disease 
and cardiovascular disease [5]. Recently, Blüher et al. [6] in-
vestigated whether the plasma concentrations of inflamma-
tory markers were associated with measures of obesity, insu-
lin sensitivity, and hyperglycemia, and discovered significant 
correlations between the plasma concentrations of all of the 
inflammatory markers examined and percent body fat, insu-
lin sensitivity, and fasting plasma glucose. Fasting plasma 
glucose was a significant determinant of adiponectin, CRP, 
and IL-6 plasma concentrations, whereas body fat content 
was a significant predictor only of CRP plasma concentration 
[6]. In a similar study, the authors concluded that type 2 DM 
was highest among subjects with elevated levels of IL-18 and 
CRP or IL-18 and IL-6. 
CRP is an acute-phase reactant synthesized by the liver in 
response to inflammatory cytokines, IL-6, IL-1, and tumor 
necrosis factor-alpha (TNF-α). Circulating CRP levels are a 
marker of systemic inflammation and are associated with 
periodontal disease [7], a chronic bacterial infection associat-
ed with the elevation of proinflammatory cytokines and pros-
taglandin [8]. Elevated immunoglobulin G induced by bacte-
rial species associated with destructive periodontal diseases 
is associated with the increase in CRP [9]. Standard non-sur-
gical periodontal therapy resulted in a decrease in serum CRP 
levels [10] in a previous study.
Microbial components, especially lipopolysaccharide, acti-
vate macrophages to synthesize and secrete a variety of pro-
inflammatory molecules, including the cytokines IL-1 and 
TNF-α; prostaglandins, especially prostaglandin E2; and hy-
drolytic enzymes. Similarly, bacterial substances activate T 
lymphocytes to produce IL-1 and lymphotoxin, a molecule 
with similar properties to TNF-α. These cytokines manifest 
potent proinflammatory and catabolic activities, and play key 
roles in periodontal tissue breakdown through collagenolytic 
enzymes such as matrix metalloproteinases (MMPs) [11]. 
The MMPs are a family of structurally and functionally re-
lated enzymes that are responsible for the proteolytic degra-
dation of extracellular matrix components. More than 20 dif-
ferent MMPs have been identified. These proteins can be 
classified into the following subgroups based on their sub-
strate specificities and structural homologies: collagenase 
(MMP-1, -8, and -13), gelatinase (MMP-2, and -9), stromelysin 
(MMP-3, -10, and -11), membrane-type MMPs (MT-MMPs- : 
MMP-14, 15, -16, -17, -23, -24, and -25) and other MMPs, inclu-
ding matrilysin (MMP-7) and metalloelastase (MMP-12) [12]. 
Expression of MMPs is low in normal cells, and these low 
levels allow for healthy connective tissue remodeling. In pa-
thologic conditions, however, the level of MMP expression 
increases considerably, resulting in aberrant connective tis-
sue destruction. Excess MMP production is associated with 
the pathology of many diseases, including periodontitis [13], 
atherosclerosis [14], tumor invasion/metastasis, and arthritic 
disease [15]. 
MT-MMPs are a unique class of MMPs anchored to the 
cell surface by transmembrane domains. MT-MMPs display 
a broad spectrum of activities, and because of their localiza-
tion to the cell surface, they are thought to play a major role 
in controlling proteolytic events within the pericellular mi-
croenvironment. MT1-MMP (MMP-14), can degrade a vari-
ety of extracellular matrix proteins and, is capable of activat-
ing both pro-MMP-2 and pro-MMP-13 [16].
MMP-17 and 25 are glycosylphosphatidylinositol-anchored 
whereas the other four MT-MMPs are type 1 transmembrane 
proteins with short cytoplasmic domains of about 20 amino 
acids. Like secreted MMPs, MT-MMPs can cleave extracellu-
lar matrix molecules, as well as chemokines, cytokines, and 
growth factors [17]. MT-MMPs are generally thought to play 
important regulatory roles because of their ability to cleave 
substrates in the immediate vicinity of the cell membrane, 
where the cleaved products can interact with cell-surface re-
ceptors. In addition, MT-MMPs are known to cleave and ac-
tivate secreted MMPs, which were first described in the case 
of activation of MMP-2 by MMP-14 through interaction with 
TIMP-2.
MMPs are regulated at several levels including transcrip-
tion, secretion, activation, and inhibition. Regulation by the 
latest of these mechanisms is via endogenous inhibitors, 
known as TIMPs. The balance between the levels of active 
enzymes and free TIMPs is thought to determine overall 
MMP activity. The TIMPs are small proteins (-23kDa) that in-
hibit MMP activity by binding to them in a 1:1 stoichiomet-
ric ratio [18]. The four members of the TIMP family (TIMP-1 
through TIMP-4) are cysteine-rich proteins stabilized by di-
sulphide bonds [19]. They are composed of a large N-termi-
nal domain responsible for MMP inhibition and a smaller C-
terminal domain. The TIMPs in general do not demonstrate 
specificity for any particular MMP [18], although TIMP-2 shows 
some degree of preference for MMP-2 and TIMP-1 for MMP- 
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TIMP-2 plays a role not only in MMP inhibition, but also 
MMP activation. The relative levels of TIMP-2 and MMP-14 
are critical, since low TIMP-2 levels are associated with MMP- 
14 mediated activation of pro-MMP-2 and at higher TIMP-2 
levels MT1-MMP function is blocked, preventing pro-MMP-2 
activation [21].
The particular roles and substrate specificities of MT-MMPs 
and TIMP-2 have not been described in detail, and the role 
of MT-MMPs and TIMP-2 in DM is unknown. 
In inflammatory responses with bone resorption, the roles 
and interactions of CRP, MMP-14, and TIMP-2 are not clear. 
Their contribution to the pathogenesis of periodontitis and 
alveolar bone resorption has not yet been established. More-
over, no in vivo studies have simultaneously analyzed CRP, 
MMP-14, and TIMP-2, and their interrelationship in diabetic 
and nondiabetic patients with chronic periodontitis. The pur-
pose of this study was to compare and quantify the expres-
sions of CRP, MMP-14, and TIMP-2, in gingival tissues in or-
der to reveal diagnostic factors in chronic periodontitis pa-
tients with or without type 2 DM. 
MATERIALS AND METHODS
Study population and tissue sampling
The study population consisted of 12 patients with type 2 
DM and chronic periodontitis, 12 patients with chronic peri-
odontitis, and 12 healthy individuals. Marginal gingival tissue 
samples were obtained in the Department of Periodontology, 
Kyungpook National University Hospital, Korea, by internal 
bevel incision at the time of periodontal surgery (including 
surgical crown lengthening) or tooth extraction. All partici-
pants signed the Institutional Review Board-approved (No. 
74  005-418) consent form prior to surgery.
According to the patient’s systemic condition (age, sex, blood 
glucose level, obesity, and smoking), the clinical criteria of 
the gingiva (sulcus bleeding index value and probing depths), 
and radiographic evidence of bone resorption, each gingival 
sample was assigned to one of three groups. Group 1 (normal, 
n=12) consisted of clinically healthy gingiva without bleed-
ing, evidence of bone resorption, or periodontal pockets, ob-
tained from 12 systemically healthy patients. Group 2 (chronic 
periodontitis, n=12) consisted of the inflamed gingiva of pa-
tients with chronic periodontitis. The diagnosis of chronic 
periodontitis was established on the basis of clinical and ra-
diographic criteria (bone resorption) according to the classi-
fication system for periodontal disease and conditions. All 
patients in group 2 were systemically healthy and had more 
than one periodontal pockets ≥5 mm and at least one pocket 
with ≥5 mm loss of attachment. All gingival samples were 
obtained from teeth with a probing depth ≥5 mm, swelling 
of the marginal gingiva, and bleeding corresponding to gin-
gival sulcus bleeding index 3 according to Mühlemann and 
Son [22]. Group 3 (chronic periodontitis and type 2 DM, n=12) 
consisted of the inflamed gingiva of patients with chronic 
periodontitis associated with type 2 DM. Patients in group 3 
were diagnosed with type 2 DM at least 6 months prior and 
showed blood glucose levels of 200 mg/dL and above in the 
first postprandial 2 hours. Patients in groups 2 and 3 had sim-
ilar periodontal conditions, but patients in group 2 were sys-
temically healthy and patients in group 3 had type 2 DM. Gin-
gival samples were obtained as described above. Patient char-
acteristics are presented in Table 1. 
Following surgery, excised tissue specimens were immedi-
ately frozen in liquid nitrogen at -70°C.
Protein isolation and western blotting 
The western blotting, technique has been as previously de-
scribed by Park and Lee [13]. Frozen tissues were homo  genized 
in radio-immunoprecipitation assay lysis buffer (10 mM eth-
ylenediaminetetraacetic acid, 0.15 M NaCl) with 1:30 diluted 
protease inhibitor cocktail (Roche, Mannheim, Germany). The 
lysates were sonicated three times for 10 seconds and centri-
fuged at 12,000 g for 20 minutes. Protein concentrations of 
the supernatant were routinely determined by a Braford pro-
tein asssay (Quick Start, BIO-rad Laboratories Inc., Hercules, 
CA, USA) using bovine serum albumin (BSA) as standard. 
Lysates were boiled in a sodium dodecyl sulfate (SDS) sam-
ple buffer (1 M Tris-HCl [pH 6.8], 40% glycerol, 8% SDS, 2% 
mercapto-ethanol, 0.002% Bromophenol blue). Prepared 
samples were separated by 15% SDS-polyacrylamide gels and 
transferred to a polyvinylidene difluoride membrane.
The membranes were subsequently blocked in tris-buff-
ered saline (TBS) containing 5% powdered milk and 1% BSA 
for 1 hour, and then incubated with polyclonal anti-CRP anti-
body, anti-MMP-14 antibody, and anti-TIMP-2 antibody (San-
ta Cruz Biotechnology Inc., Santa Cruz, CA, USA) for 1.5 hours 
at room temperature.
The membranes were washed (five times for 5 minutes with 
Tween 20) and incubated with a horseradish peroxidase-con-
jugated goat anti-rabbit secondary antibody for anti-CRP an-
Table 1. Patient characteristics.
Group 1 (n=12) Group 2 (n=12) Group 3 (n=12)
Gender (M:F) 6:6 6:6 6:6
Age (yr), mean (range) 33.6 (21-43) 48.2 (41-52) 50.4 (44-54)
Probing depth (mean, mm) 2.0 8.0 7.0
Smokers 0 0 0
Postprandial glucose 90 103 289
level (mg/dL)Journal of Periodontal
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tibody, anti-MMP-14 antibody, and anti-TIMP-2 antibody 
(diluted 1:2,000 in TBS) for 1 hour at room temperature. Af-
ter additional washing (five times for 5 minutes with Tween 
20) the western blot procedure was completed with an ECL 
Plus development kit (Amsterdam, Beckinghamshire, UK). 
The relative quantification analysis of CRP, MMP-14, and 
TIMP-2 expression was performed using a densitometer (Ima-
ge Gauge V 3.46, Fuji Photo Film Co., Tokyo, Japan). After nor-
malization to β-actin (Abcam plc, Cambri  dge, UK) in each 
sample, levels of CRP, MMP-14, and TIMP-2 were expressed 
as a ratio of CRP, MMP-14, or TIMP-2 to β- actin and the dif-
ferences in density between the 3 groups were determined.
Statistical analysis of the western blot results 
All data were presented as means±standard deviation and 
results were statistically analyzed. The CRP, MMP-14, and 
TIMP-2 levels were compared using a one-way analysis of 
vaiance followed by Tukey’s test. P-value <0.05 was consid-
ered to statistically significant.
RESULTS
Representative western blot data comparing CRP expres-
sion levels in human gingiva with chronic periodontitis with 
or without type 2 DM are presented in Fig. 1. The compari-
son of CRP expression levels were also studied by detecting a 
CRP band with a molecular weight of about 27 kDa and mea-
suring their density and areas in all three groups (Fig. 1). The 
comparative levels of normalized CRP expression are given 
in Fig. 2. The mean value of CRP expression (ratio of CRP/
β-actin) was 0.669±0.119 for group 1, 0.679±0.134 for group 2, 
and 0.859±0.186 for group 3. There were statistically signifi-
cant differences between group 1 and group 3 and between 
group 2 and group 3, but there was no statistically significant 
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Figure 1. C-reactive protein (CRP) western analysis showing 4 rep-
resentative blots in each group. C-reactive protein levels were quan-
tified on the basis of β-actin levels. CRP corresponding to a molec-
ular weight of 27 kDa was expressed in all groups, including healthy 
gingiva, and the expression levels of C-reactive protein increased in 
order from group 1 to group 2 to group 3. Group 1, healthy gingiva 
from systemically healthy persons; Group 2, inflamed gingiva from 
patients with chronic periodontitis; Group 3, inflamed gingiva from 
patients with chronic periodontitis and type 2 diabetes mellitus.
parison of MMP-14 expression levels was also performed by 
western blot analysis using MMP-14 specific antibody which 
detected MMP-14 in all three groups (Fig. 3). The compara-
tive levels of MMP-14 expression were also quantified with 
β-actin normalization (Fig. 4). The mean value of MMP-14 
expression (ratio of MMP-14/β-actin) was 0.542±0.104 for 
group 1, 0.706±0.133 for group 2, and 0.954±0.248 for group 3. 
There were statistically significant differences between group 
1 and group 2 (P<0.05) and between group 1 and group 3 (P< 
0.05). In this study, the molecular weight of TIMP-2 was iden-
tified to be 28 kDa in western blot analysis (Fig. 5). The com-
parative levels of TIMP-2 expression were also quantified with 
β-actin normalization and presented in Fig. 6. The mean val-
ue of TIMP-2 expression (ratio of TIMP-2/β-actin) was 0.485± 
0.098 for group 1, 0.605±0.084 for group 2, and 0.746±0.181 
for group 3. There were statistically significant differences 
between group 1 and group 3 and between group 2 and group 
3 (P<0.05).
Figure 2. C-reactive protein (CRP) levels (ratio of CRP/β-actin) in 
groups 1, 2, and 3. In inflamed gingiva with diabetes (group 3), the 
levels of CRP were significantly increased as compared to group 1 
and group 2 (P<0.05). 
a)Significant difference between group 1 and 
group 3 (P<0.05). 
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Figure 3. Matrix metalloproteinase (MMP)-14 western analysis show-
ing 4 representative blots in each group. MMP-14 levels were quan-
tified on the basis of β-actin levels. MMP-14 corresponding to a mol-
ecular weight of 60 kDa was shown to be expressed in all groups in-
cluding healthy gingiva. The expression levels of Matrix metallo-
proteinase 14 increased in order from group 1 to group 2 to group 3. 
Group 1, healthy gingiva from systemically healthy persons; Group 
2, inflamed gingiva from patients with chronic periodontitis; Group 
3, inflamed gingiva from patients with chronic periodontitis and 
type 2 diabetes mellitus.Journal of Periodontal
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DISCUSSION 
Among the many oral problems that can occur because of 
diabetes, the prevalence of severe periodontitis is significant-
ly higher among people with poorly controlled DM [23], to 
the extent that periodontitis has been called the “sixth com-
plication of diabetes” [24]. The reason for the higher rates of 
periodontal disease in people with diabetes is not completely 
understood, but studies have reported that there is little dif-
ference in the periodontal flora of people with and without 
DM, and suggest that the increased destruction of tissue 
among those with diabetes may be due to an altered host 
susceptibility to periodontal pathogens mediated by the ac-
cumulation of advanced glycation end products in the tis-
sues, microvascular changes, and perhaps impaired lipid me-
tabolism [25]. Conversely, these data also suggest that the 
presence of periodontal infection can adversely affect glyce-
mic control in people with diabetes and that there appears to 
be a bi-directional relationship between the two conditions.
The purpose of this study was to quantify and compare the 
expression of CRP, MMP-14 and TIMP-2 in the gingival tis-
sues of patients with chronic periodontitis associated to type 
2 DM, in order to understand the diagnostic contribution of 
these proteins to periodontal destruction accompanied with 
alveolar bone resorption in type 2 diabetic patients.
CRP is an acute-phase protein suggesting a central role in 
immunological response [26]. It is synthesized in the liver 
mainly in response to IL-6 and binds to the polysaccharides 
of pathogens promoting phagocytosis [27]. Several studies 
have shown that CRP could be useful in infection diagnosis 
[28], as well as in monitoring the response to antibiotic thera-
py [29].
In this study, the quantitative analysis of CRP levels showed 
that CRP expression increased significantly in inflamed gin-
giva with or without type 2 DM compared to healthy gingiva. 
Differences were statistically significant between group 1 and 
group 3 and between group 2 and group 3 (P<0.05) (Table 2, 
Fig. 2). 
Our results are similar to previous studies in which Noack 
et al. [7] and Craig et al. [9] found that subjects with periodon-
tal disease demonstrated higher levels of CRP than subjects 
without periodontitis. 
We found a statistically significant difference between peri-
odontitis subjects with DM (group 3) and subjects with peri-
odontitis only (group 2). The ongoing acute phase response 
(seen in insulin-resistant subjects and type II DM patients) is 
induced by cytokines, and is reflected in elevated circulating 
inflammatory markers, such as CRP, IL-1, IL-6, TNF-α, leptin, 
plasminogen activator inhibitor-1, angiotensinogen, and fi-
brinogen, as described by Hsueh and Bruemmer [30]. It seems 
Figure 4. Matrix metalloproteinase (MMP)-14 levels (ratio of MMP-
14 to β-actin) in groups 1, 2, and 3. In the inflamed gingiva (with or 
without diabetes, group 3 and group 2, respectively), the levels of 
MMP-14 were higher than those of healthy gingiva. 
a)Significant 
difference between group 1 and group 2 (P<0.05). 
b)Significant dif-
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Figure 5. Tissue inhibitor of metalloproteinase (TIMP)-2 western 
analysis showing 4 representative blots in each group. TIMP-2 levels 
were quantified on the basis of β-actin levels. TIMP-2 correspond-
ing to a molecular weight of 28 kDa was expressed in all samples in-
cluding healthy gingiva. The expression levels of TIMP-2 were in-
creased in patients with type 2 diabetes mellitus compared to healthy 
control subjects. Group 1, healthy gingiva from systemically healthy 
persons; Group 2, inflamed gingiva from patients with chronic peri-
odontitis; Group 3, inflamed gingiva from patients with chronic 
periodontitis and type 2 diabetes mellitus.
Group 1 Group 2 Group 3
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Table 2. Normalized C-reactive protein (CRP) expression by CRP/β- 
actin.
Sample Group 1 Group 2 Group 3
1 0.575 0.699 0.537
2 0.510 0.581 1.050
3 0.615 0.534 0.771
4 0.621 0.510 1.004
5 0.824 0.777 0.987
6 0.843 0.855 1.093
7 0.800 0.836 1.023
8 0.784 0.905 0.990
9 0.675 0.585 0.633
10 0.680 0.569 0.730
11 0.580 0.661 0.722
12 0.518 0.637 0.770
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that the increased levels of CRP were influenced by DM dur-
ing the progression of inflammation.
Microbial components, especially lipopolysaccharides, acti-
vate macrophages to synthesize and secrete a variety of pro-
inflammatory molecules, including the cytokines IL-1 and 
TNF-alpha, prostaglandins, especially prostaglandin E2, and 
hydrolytic enzymes. Similarly, bacterial substances activate T 
lymphocytes to produce IL-1 and lymphotoxin, a molecule 
with similar properties to TNF-alpha. These cytokines mani-
fest potent proinflammatory and catabolic activities, and play 
key roles in periodontal tissue breakdown through collagen-
olytic enzymes such as MMPs. 
MMP-14 was initially identified as the activator of MMP-2, 
but has recently been shown to be important for wound heal-
ing, angiogenesis, and inflammation [31]. It is over-expressed 
in cancers leading to migration, invasion, and metastasis [32]. 
MMP-14 activation occurs via a proprotein convertase, and 
recent data suggests that its function is modified by glycosyl-
ation, internalization and recycling [33]. Finally MMP-14 di-
rectly degrades extracellular matrix molecules, including col-
lagen type I, III, laminin, and fibronectin [34]. 
In this study, the quantitative analysis of MMP-14 levels 
showed that MMP-14 expression was rather increased in in-
flamed gingiva with or without type 2 DM compared to heal-
thy gingiva. The differences were statistically significant be-
tween group 1 and group 2 and between group 1 and group 3 
(P<0.05) (Table 3, Fig. 4).
Song and Ergul [35] reported that mild elevation of blood 
glucose for 6 weeks is sufficient to stimulate gene expression 
of MMP-2, MMP-9, and MMP-14. 
The MMP-14 level in group 3 was higher than group 2, but 
difference was not statistically significant. It can be assumed 
that this is a result of a higher inflammatory response in chro-
nic periodontitis associated with type 2 DM.
A major group of inhibitors of the MMPs, TIMP-2, has been 
studied in this study. The levels of TIMP-2 were significantly 
different between group 1 and 3 and between group 2 and 
group 3 (P<0.05) (Table 4, Fig. 6). However, there has been 
some debate over findings regarding TIMP-2 in diabetic sub-
jects. MecLennan et al. [36] observed no changes in TIMP-2 
expression in mesangial cells cultured in high glucose. Our 
results also show increased TIMP-2 levels. It can be assumed 
that this is a result of a greater inflammatory response in chro-
nic periodontitis associated with type 2 DM.
In conclusion, increased levels of CRP, MMP-14, and TIMP-
2 are useful for diagnosing and monitoring inflammatory 
Table 4. Normalized TIMP-2 expression by TIMP-2/β-actin.
Sample  Group 1 Group 2 Group 3
1 0.455 0.576 1.031
2 0.383 0.718 0.862
3 0.581 0.713 1.084
4 0.532 0.492 0.557
5 0.478 0.524 0.507
6 0.374 0.583 0.648
7 0.391 0.681 0.667
8 0.429 0.468 0.734
9 0.412 0.597 0.760
10 0.513 0.684 0.819
11 0.579 0.641 0.552
12 0.696 0.578 0.735






Table 3. Normalized MMP-14 expression by MMP-14/β-actin.
Sample Group 1 Group 2 Group 3
1 0.641 0.703 0.714
2 0.746 0.708 0.858
3 0.475 0.807 0.844
4 0.490 0.789 1.222
5 0.426 0.772 0.899
6 0.677 0.614 0.916
7 0.450 0.713 0.568
8 0.472 0.937 0.959
9 0.461 0.437 1.176
10 0.480 0.578 1.512
11 0.578 0.812 0.907








Figure 6. Tissue inhibitor of metalloproteinases (TIMP)-2 level (Ra-
tio of TIMP-2 to β-actin) in groups 1, 2, and 3. In the inflamed gingi-
va (with or without diabetes, groups 3 and 2, respectively), the levels 
of TIMP-2 were higher than those of healthy gingiva (P<0.05). 
a)Significant difference between group 1 and group 2 (P<0.05). 
b)Sig-
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disease that includes moderate periodontitis.
More studies are needed to investigate interrelationship 
among CRP, MMP-14, TIMP-2, and other factors that affect 
the progression of periodontal disease to a more advanced 
level. 
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